BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31289316)

  • 1. Reversine exhibits antineoplastic activity in JAK2
    Lima K; Carlos JAEG; Alves-Paiva RM; Vicari HP; Souza Santos FP; Hamerschlak N; Costa-Lotufo LV; Traina F; Machado-Neto JA
    Sci Rep; 2019 Jul; 9(1):9895. PubMed ID: 31289316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia.
    Carlos JAEG; Lima K; Coelho-Silva JL; de Melo Alves-Paiva R; Moreno NC; Vicari HP; de Souza Santos FP; Hamerschlak N; Costa-Lotufo LV; Traina F; Machado-Neto JA
    Cell Oncol (Dordr); 2020 Dec; 43(6):1191-1201. PubMed ID: 32857324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversine triggers mitotic catastrophe and apoptosis in K562 cells.
    Rodrigues Alves AP; Machado-Neto JA; Scheucher PS; Paiva HH; Simões BP; Rego EM; Traina F
    Leuk Res; 2016 Sep; 48():26-31. PubMed ID: 27447890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin exerts multitarget antileukemia activity in JAK2
    Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
    Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
    Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
    Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R
    Parducci NS; Garnique ADMB; Lima K; Carlos JAEG; Fonseca NP; de Miranda LBL; de Almeida BO; Rego EM; Traina F; Machado-Neto JA
    Blood Cells Mol Dis; 2024 Jan; 104():102799. PubMed ID: 37839173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
    Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
    Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
    Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
    Petiti J; Rosso V; Lo Iacono M; Panuzzo C; Calabrese C; Signorino E; Pironi L; Cartellà A; Bracco E; Pergolizzi B; Beltramo T; Fava C; Cilloni D
    J Cell Mol Med; 2019 Jun; 23(6):4349-4357. PubMed ID: 31033209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glioma cells by antineoplastic activity of reversine.
    Hirakata C; Lima K; De Almeida BO; De Miranda LBL; Florêncio KGD; Furtado LC; Costa-Lotufo LV; Machado-Neto JA
    Oncol Lett; 2021 Aug; 22(2):610. PubMed ID: 34188712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.
    Machado-Neto JA; de Melo Campos P; Favaro P; Lazarini M; da Silva Santos Duarte A; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Oncotarget; 2015 Oct; 6(30):29573-84. PubMed ID: 26356819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential killing of p53-deficient cancer cells by reversine.
    Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G
    Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
    Yu Z; Sun Y; She X; Wang Z; Chen S; Deng Z; Zhang Y; Liu Q; Liu Q; Zhao C; Li P; Liu C; Feng J; Fu H; Li G; Wu M
    J Hematol Oncol; 2017 Jun; 10(1):115. PubMed ID: 28595628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring redox vulnerabilities in JAK2
    Lima K; Lopes LR; Machado-Neto JA
    Hematol Transfus Cell Ther; 2021; 43(4):430-436. PubMed ID: 32962959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression.
    Woo JK; Kang JH; Shin D; Park SH; Kang K; Nho CW; Seong JK; Lee SJ; Oh SH
    Mol Cancer Ther; 2015 Jul; 14(7):1693-704. PubMed ID: 25882311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.